|DEDONDER, KEITH - Kansas State University|
|APLEY, MICHAEL - Kansas State University|
|WHITE, BRADLEY - Kansas State University|
|LARSON, ROBERT - Kansas State University|
|CAPIK, SARA - Kansas State University|
|LUBBERS, BRIAN - Kansas State University|
|Clawson, Michael - Mike|
Submitted to: Meeting Abstract
Publication Type: Abstract Only
Publication Acceptance Date: 10/16/2015
Publication Date: 12/6/2015
Citation: Chitko-McKown, C.G., Workman, A.M., DeDonder, K.D., Bennett, G.L., Apley, M.D., Harhay, G.P., Harhay, D.M., Kuehn, L.A., White, B.J., Larson, R.L., Capik, S.F., Lubbers, B.V., Clawson, M.L. 2015. Comparison of serum PTX3 from shipping through sickness and recovery in cattle [Abstract]. Conference of Research Workers in Animal Diseases, December 6-8, 2015, Chicago, IL. Abstract #070P.
Technical Abstract: Infectious respiratory diseases of ruminant are a serious health and economic problem for U.S. agriculture. In cattle alone, bovine respiratory disease complex (BRDC) costs the feedlot industry approximately 1 billion dollars annually. The level of resistance or susceptibility an animal has to one of the bacterial or viral pathogens of BRDC can be at least partly linked to the competence of its innate immune response – that arm of immunity that is not dependent upon vaccination or prior exposure to infectious insult in order to respond. Pentraxin-related protein 3 (PTX3) acts as an acute phase protein in response to infection and inflammation, and blood levels are often associated with outcome and/or severity of disease. PTX3 plays a role in innate resistance to viral infections such as cytomegalovirus and influenza virus, as well as to chronic lung infections caused by P. aeruginosa and K. pneumonia. At this time, the role of PTX3 in BRDC is unknown. Our objectives were to determine if PTX3 concentrations in serum differed between sham- and mass-medicated treatment groups, and if it differed between animals presenting with BRDC and those that remained healthy throughout a 28 day trial regardless of antibiotic use. Sixty head of cattle were purchased at each of three sale barns located in MO, TN, and KY for a total of 180 animals on trial. Cattle were transported to a feeding facility in KS where they were randomly allocated within source to one of two treatments, mass-medication with gamithromycin (n = 90) or sham saline-injection treatment (n = 90). Blood samples were collected for plasma at Day 0 (at sale barn), Day 1 (at KS facility), Day 9, and Day 28. Cattle presenting with BRDC were also sampled for plasma at the time of diagnosis and 5 days later. The plasma samples were assayed for bovine PTX3 using a commercial quantitative sandwich ELISA. Of the 180 cattle on trial, 28 presented with BRDC. These cases were matched with control (healthy) animals from the same treatment, pen, and sale barn. Preliminary data thus far indicates that PTX3 concentrations do not correlate with BRDC or treatment. Additional analysis is on-going. USDA is an equal opportunity provider and employer.